EUVIMEDEUVIMED entdecken
Crossref

A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome

Hui Liu iD, Kai Ding, Wei Zhang iD, Limin Xing, Yihao Wang, Huaquan Wang iD, Jia Song, Lijuan Li, Rong Fu iD

British Journal of Haematology · 2024-03 · 204 (3) · 1082-1085

DOI: 10.1111/bjh.19146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 06.11.2023. Verfasst von Hui Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University General Hospital, Tianjin, P.R. China. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, Piperidines, Pyridines, Thrombocytopenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Tianjin Education Commission Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, there is no effective treatment for refractory/relapsed (R/R) autoimmune haemolytic anaemia (AIHA), associated with poor quality of life. Bruton tyrosine kinase inhibitors have begun to be used in some autoimmune diseases. We initiated the clinical trial of orelabrutinib treatment on R/R AIHA/Evans Syndrome, which is in progress. The preliminary results showed that nine of the 12 enrolled patients responded to orelabrutinib treatment. Here, we reported three cases who have completed the treatment and were followed up for 6 months, achieving complete or partial remission. Orelabrutinib is expected to become a new second‐line treatment for R/R AIHA/Evans syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Hemolytic, AutoimmunePiperidinesPyridinesThrombocytopeniaHumansPilot ProjectsQuality of Life

Stichwörter der Autor:innen

Evans syndromeautoimmune haemolytic anaemiaorelabrutinibrefractoryrelapsed

Substanzen

orelabrutinibPiperidinesPyridines

Autor:innen und Institutionen

  • Tianjin Medical University General Hospital, Tianjin, P.R. China.

ORCID-Profile: Hui Liu, Wei Zhang, Huaquan Wang, Rong Fu

Förderung

  • Tianjin Education Commission Research Project

Zitieren

APA

Liu, H., Ding, K., Zhang, W., Xing, L., Wang, Y., Wang, H., Song, J., Li, L., & Fu, R. (2024). A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome. British Journal of Haematology, 204(3), 1082-1085. https://doi.org/10.1111/bjh.19146

Vancouver

Liu H, Ding K, Zhang W, Xing L, Wang Y, Wang H, et al. A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome. British Journal of Haematology. 2024;204(3):1082-1085. doi:10.1111/bjh.19146

BibTeX
@article{Liu2024,
  author = {Liu, Hui and Ding, Kai and Zhang, Wei and Xing, Limin and Wang, Yihao and Wang, Huaquan and Song, Jia and Li, Lijuan and Fu, Rong},
  title = {A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {204},
  number = {3},
  pages = {1082--1085},
  doi = {10.1111/bjh.19146}
}
Kostenlos starten →